ACT IV: the final act for rindopepimut?
Lancet Oncol
.
2017 Oct;18(10):1294-1296.
doi: 10.1016/S1470-2045(17)30619-8.
Epub 2017 Aug 23.
Author
Elizabeth R Gerstner
1
Affiliation
1
Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: egerstner@partners.org.
PMID:
28844498
DOI:
10.1016/S1470-2045(17)30619-8
No abstract available
Publication types
Comment
MeSH terms
Cancer Vaccines*
Glioblastoma*
Humans
United States
Vaccines, Subunit
Substances
Cancer Vaccines
Vaccines, Subunit
rindopepimut